{"id":4754,"date":"2025-12-17T09:37:01","date_gmt":"2025-12-17T08:37:01","guid":{"rendered":"https:\/\/www.access2meds.eu\/?p=4754"},"modified":"2025-12-17T09:37:09","modified_gmt":"2025-12-17T08:37:09","slug":"new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe","status":"publish","type":"post","link":"https:\/\/www.access2meds.eu\/ro\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/","title":{"rendered":"New ASCERTAIN video series explains how medicines are priced, evaluated and made available in Europe"},"content":{"rendered":"\n<p>The short videos are part of ASCERTAIN\u2019s commitment to transparency and patient engagement. They explain key concepts that play an important role in how new medicines and medical devices are evaluated, priced, and ultimately made accessible to patients across Europe.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-what-is-a-model\">What is a model?<\/h4>\n\n\n\n<p>The first video introduces health economic models. These are tools used to analyse information and compare different strategies when making decisions about healthcare interventions. The video explains how models help decision-makers assess costs, value for patients and health systems, affordability and broader societal impacts, including environmental considerations. It also shows who uses these models, from regulators and HTA agencies to companies, policymakers, and patient organisations.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.youtube.com\/watch?v=JgCt_3FW6mg\">Watch video on YouTube.<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-what-is-a-framework\">What is a framework?<\/h4>\n\n\n\n<p>The second video focuses on the ACCESS2MEDS framework developed within ASCERTAIN. It explains how a framework brings together different models for pricing, cost-effectiveness, and reimbursement into one structured approach. The video highlights how such frameworks support more consistent, transparent, and well-informed decision-making, particularly in the context of increasing pressure on public health budgets.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.youtube.com\/watch?v=E0ZmPm-ph48\">Watch video on YouTube.<\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-the-journey-of-a-new-medicine-in-the-eu\">The journey of a new medicine in the EU<\/h4>\n\n\n\n<p>The third video follows the journey of a new medicine from research and development to patient use. It explains the role of the European Medicines Agency, the scientific evaluation process, market authorisation at EU level and the national decisions on pricing and reimbursement that ultimately determine patient access in each country.<\/p>\n\n\n\n<p><a href=\"https:\/\/www.youtube.com\/watch?v=kUKLk_xeTTg\">Watch video on YouTube.<\/a><\/p>\n\n\n\n<p>All three videos are animated, easy to follow, and aimed at helping patients and the wider public better understand how decisions about medicines are made.<\/p>\n\n\n\n<p>You can find these videos and more patient-focused resources on the ASCERTAIN website: <a href=\"https:\/\/www.access2meds.eu\/for-patients\/\">https:\/\/www.access2meds.eu\/for-patients\/<\/a><\/p>\n\n\n\n<p>Thanks to Myeloma Patients Europe for developing these videos.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>ASCERTAIN has launched a new animated video series designed to make complex topics around medicine pricing, cost-effectiveness, reimbursement, and decision-making in the European Union easier to understand.<\/p>\n","protected":false},"author":5,"featured_media":1450,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1],"tags":[21,14,22,23,20],"class_list":["post-4754","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-allgemein","tag-health-technologies","tag-healthcare","tag-hta","tag-iht","tag-innovative-health-technologies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.8 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>New ASCERTAIN video series explains how medicines are priced, evaluated and made available in Europe - ASCERTAIN<\/title>\n<meta name=\"description\" content=\"ASCERTAIN has launched a new animated video series designed to make complex topics around medicine pricing, cost-effectiveness, reimbursement, and decision-making in the European Union easier to understand.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/\" \/>\n<meta property=\"og:locale\" content=\"ro_RO\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New ASCERTAIN video series explains how medicines are priced, evaluated and made available in Europe\" \/>\n<meta property=\"og:description\" content=\"ASCERTAIN has launched a new animated video series designed to make complex topics around medicine pricing, cost-effectiveness, reimbursement, and decision-making in the European Union easier to understand.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/\" \/>\n<meta property=\"og:site_name\" content=\"ASCERTAIN\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-17T08:37:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-17T08:37:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2005\" \/>\n\t<meta property=\"og:image:height\" content=\"1254\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lena Jessen\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:site\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:label1\" content=\"Scris de\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lena Jessen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Timp estimat pentru citire\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/\"},\"author\":{\"name\":\"Lena Jessen\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/person\\\/84cb4791d2eba62e68ecb7f29dba9391\"},\"headline\":\"New ASCERTAIN video series explains how medicines are priced, evaluated and made available in Europe\",\"datePublished\":\"2025-12-17T08:37:01+00:00\",\"dateModified\":\"2025-12-17T08:37:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/\"},\"wordCount\":308,\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"keywords\":[\"health technologies\",\"healthcare\",\"HTA\",\"iht\",\"innovative health technologies\"],\"articleSection\":[\"Allgemein\"],\"inLanguage\":\"ro-RO\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/\",\"name\":\"New ASCERTAIN video series explains how medicines are priced, evaluated and made available in Europe - ASCERTAIN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"datePublished\":\"2025-12-17T08:37:01+00:00\",\"dateModified\":\"2025-12-17T08:37:09+00:00\",\"description\":\"ASCERTAIN has launched a new animated video series designed to make complex topics around medicine pricing, cost-effectiveness, reimbursement, and decision-making in the European Union easier to understand.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/#breadcrumb\"},\"inLanguage\":\"ro-RO\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"width\":2005,\"height\":1254},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.access2meds.eu\\\/ro\\\/startseite\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New ASCERTAIN video series explains how medicines are priced, evaluated and made available in Europe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"name\":\"ASCERTAIN\",\"description\":\"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.access2meds.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ro-RO\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\",\"name\":\"ASCERTAIN\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ro-RO\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"ASCERTAIN\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/ASCERTAIN_EU\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ascertain-eu\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@ascertainproject\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/person\\\/84cb4791d2eba62e68ecb7f29dba9391\",\"name\":\"Lena Jessen\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"New ASCERTAIN video series explains how medicines are priced, evaluated and made available in Europe - ASCERTAIN","description":"ASCERTAIN has launched a new animated video series designed to make complex topics around medicine pricing, cost-effectiveness, reimbursement, and decision-making in the European Union easier to understand.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/","og_locale":"ro_RO","og_type":"article","og_title":"New ASCERTAIN video series explains how medicines are priced, evaluated and made available in Europe","og_description":"ASCERTAIN has launched a new animated video series designed to make complex topics around medicine pricing, cost-effectiveness, reimbursement, and decision-making in the European Union easier to understand.","og_url":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/","og_site_name":"ASCERTAIN","article_published_time":"2025-12-17T08:37:01+00:00","article_modified_time":"2025-12-17T08:37:09+00:00","og_image":[{"width":2005,"height":1254,"url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","type":"image\/jpeg"}],"author":"Lena Jessen","twitter_card":"summary_large_image","twitter_creator":"@ASCERTAIN_EU","twitter_site":"@ASCERTAIN_EU","twitter_misc":{"Scris de":"Lena Jessen","Timp estimat pentru citire":"2 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/#article","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/"},"author":{"name":"Lena Jessen","@id":"https:\/\/www.access2meds.eu\/#\/schema\/person\/84cb4791d2eba62e68ecb7f29dba9391"},"headline":"New ASCERTAIN video series explains how medicines are priced, evaluated and made available in Europe","datePublished":"2025-12-17T08:37:01+00:00","dateModified":"2025-12-17T08:37:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/"},"wordCount":308,"publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"image":{"@id":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","keywords":["health technologies","healthcare","HTA","iht","innovative health technologies"],"articleSection":["Allgemein"],"inLanguage":"ro-RO"},{"@type":"WebPage","@id":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/","url":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/","name":"New ASCERTAIN video series explains how medicines are priced, evaluated and made available in Europe - ASCERTAIN","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/#primaryimage"},"image":{"@id":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","datePublished":"2025-12-17T08:37:01+00:00","dateModified":"2025-12-17T08:37:09+00:00","description":"ASCERTAIN has launched a new animated video series designed to make complex topics around medicine pricing, cost-effectiveness, reimbursement, and decision-making in the European Union easier to understand.","breadcrumb":{"@id":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/#breadcrumb"},"inLanguage":"ro-RO","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/"]}]},{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/#primaryimage","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","width":2005,"height":1254},{"@type":"BreadcrumbList","@id":"https:\/\/www.access2meds.eu\/new-ascertain-video-series-explains-how-medicines-are-priced-evaluated-and-made-available-in-europe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.access2meds.eu\/ro\/startseite\/"},{"@type":"ListItem","position":2,"name":"New ASCERTAIN video series explains how medicines are priced, evaluated and made available in Europe"}]},{"@type":"WebSite","@id":"https:\/\/www.access2meds.eu\/#website","url":"https:\/\/www.access2meds.eu\/","name":"ASCERTAIN","description":"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES","publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.access2meds.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ro-RO"},{"@type":"Organization","@id":"https:\/\/www.access2meds.eu\/#organization","name":"ASCERTAIN","url":"https:\/\/www.access2meds.eu\/","logo":{"@type":"ImageObject","inLanguage":"ro-RO","@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","width":1,"height":1,"caption":"ASCERTAIN"},"image":{"@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ASCERTAIN_EU","https:\/\/www.linkedin.com\/company\/ascertain-eu\/","https:\/\/www.youtube.com\/@ascertainproject"]},{"@type":"Person","@id":"https:\/\/www.access2meds.eu\/#\/schema\/person\/84cb4791d2eba62e68ecb7f29dba9391","name":"Lena Jessen"}]}},"_links":{"self":[{"href":"https:\/\/www.access2meds.eu\/ro\/wp-json\/wp\/v2\/posts\/4754","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.access2meds.eu\/ro\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.access2meds.eu\/ro\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/ro\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/ro\/wp-json\/wp\/v2\/comments?post=4754"}],"version-history":[{"count":1,"href":"https:\/\/www.access2meds.eu\/ro\/wp-json\/wp\/v2\/posts\/4754\/revisions"}],"predecessor-version":[{"id":4761,"href":"https:\/\/www.access2meds.eu\/ro\/wp-json\/wp\/v2\/posts\/4754\/revisions\/4761"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/ro\/wp-json\/wp\/v2\/media\/1450"}],"wp:attachment":[{"href":"https:\/\/www.access2meds.eu\/ro\/wp-json\/wp\/v2\/media?parent=4754"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.access2meds.eu\/ro\/wp-json\/wp\/v2\/categories?post=4754"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.access2meds.eu\/ro\/wp-json\/wp\/v2\/tags?post=4754"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}